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Abstract
Background: The development of HIV drug resistance and subsequent virological failure are often cited as potential
disadvantages of early cART initiation. However, their long-term probability is not known, and neither is the role of
duration of infection at the time of initiation.
Methods: Patients enrolled in the UK Register of HIV seroconverters were followed-up from cART initiation to last
HIV-RNA measurement. Through survival analysis we examined predictors of virologic failure (2HIV-RNA ≥400 c/l
while on cART) including CD4 count and HIV duration at initiation. We also estimated the cumulative probabilities of
failure and drug resistance (from the available HIV nucleotide sequences) for early initiators (cART within 12 months
of seroconversion).
Results: Of 1075 starting cART at a median (IQR) CD4 count 272 (190,370) cells/mm3 and HIV duration 3 (1,6)
years, virological failure occurred in 163 (15%). Higher CD4 count at initiation, but not HIV infection duration at cART
initiation, was independently associated with lower risk of failure (p=0.033 and 0.592 respectively). Among 230
patients initiating cART early, 97 (42%) discontinued it after a median of 7 months; cumulative probabilities of
resistance and failure by 8 years were 7% (95% CI 4,11) and 19% (13,25), respectively.
Conclusion: Although the rate of discontinuation of early cART in our cohort was high, the long-term rate of
virological failure was low. Our data do not support early cART initiation being associated with increased risk of
failure and drug resistance.
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Introduction
Since combination antiretroviral therapy (cART) was
introduced in the mid-1990s there has been a trend towards
initiating it earlier in the course of HIV disease. Some major
treatment guidelines currently recommend initiation when CD4
cells count drops below 350 cells/mm3 while others at CD4 cell
count below 500 cells/mm3 or in all patients with diagnosed HIV
infection (e.g. [1-4]). Moreover, the “test and treat” approach of
testing whole populations for HIV followed by immediate
initiation of cART for all infected, regardless of CD4 cell count,
has gained stimulus as a potential tool for the prevention of
onward HIV transmission. Such an approach would result in
greater numbers initiating cART in early infection [5-7].
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A potential disadvantage of early cART initiation, however, is
risk of failure and subsequent development of drug resistance.
This is driven by concern that asymptomatic individuals with
low absolute risk of clinical disease, who may not be ready to
commit to life-long cART, might be at raised risk of developing
drug resistance due to sub-optimal adherence. This concern
was not supported by a number of studies showing that higher
CD4 cell count at cART initiation was associated with lower risk
of drug resistance [8-10]. Nonetheless, there are no published
data on the long-term risk of developing resistance following
early treatment initiation, or on the role of duration of HIV
infection at initiation as a predictor of virological failure or of
resistance. These data are important to inform the debate on
when to initiate treatment.
We have, therefore, used data from the UK Register of HIV
Seroconverters to estimate the risk of virological failure while
on cART as a proxy of development of drug resistance in
patients who initiated cART in early HIV infection, and to
assess duration of infection at cART initiation as a predictor of
failure. In a subset of patients, for whom HIV nucleotide
sequences were available, we also examined the role of HIV
infection duration on the long-term risk of drug resistance. Our
study hypothesis is that shorter duration of HIV infection at
cART initiation is associated with increased risk of virological
failure and development of drug resistance.
Methods
Patients
The UK Register of HIV Seroconverters is a cohort
established in October 1994 with the initial aim of studying the
natural history of HIV infection [11]. Eligible patients are aged
>15 years with a positive HIV test result within 3 years of a
negative HIV antibody test result, or with laboratory evidence of
acute infection. Since 2004 the eligibility criteria were narrowed
to include only individuals with an HIV test interval of ≤12
months although those already enrolled remained under follow-
up. In 2011 the eligibility criteria were widened to allow the
follow-up of perinatally-infected children originally enrolled in
the Collaborative HIV Paediatric Study (CHIPS)
[www.chipscohort.ac.uk] once they reached >15 years of age.
Data are collected at enrolment and annually thereafter,
through Clinical Report Forms at clinical centres, and include
demographic information, laboratory measurements (including
CD4 count and HIV-RNA), details of all antiretroviral therapy
prescribed, clinical events and vital status. We used the data
updated in September 2011 excluding perinatally-infected
children.
We included patients enrolled in the UK Register of HIV
Seroconverters who initiated cART aged >15 years, while naive
at cART initiation and with at least one CD4 count in the 6
months before initiation, and at least one HIV-RNA
measurement >6 months after initiation. We also identified the
subgroup of patients who had initiated cART early, i.e. within
12 months of HIV seroconversion.
Failure was defined as the first of two consecutive HIV-RNA
measurements ≥400 copies/mL after 6 months of cART
initiation while the patient was known to be on at least one
antiretroviral drug. Episodes of HIV-RNA ≥400 copies/mL
occurring while the patient was not on ART were not
considered as virological failure as they were likely to be a
consequence of stopping cART rather than virological failure.
cART was defined as a combination of at least three drugs
from at least two classes, or at least three nucleoside reverse-
transcriptase inhibitors, one of which was tenofovir or abacavir.
Statistical analyses
Follow-up started at date of cART initiation and ended at last
recorded HIV-RNA measurement.
Univariable and multivariable Cox proportional hazard
models were then used to examine the association between
failure and duration of infection at cART initiation since the
estimated date of HIV seroconversion (0-3, 4-12, >12 months)
adjusting for the potential effects of: age, and CD4 count
(natural log scale) at cART initiation, sex, risk group, class of
initial cART, calendar year of initiation (<2000 vs. ≥2000), and
diagnosis during acute HIV infection (HIV test interval <30
days/ laboratory evidence of acute infection vs. longer test
interval). The choice for calendar year cut-off reflected the
introduction of boosted protease inhibitors (PIs). Models using
fractional polynomials indicated a non-linear age effect on
survival and two age groups based on median age at
seroconversion (<36 and ≥36 years) were, therefore, used [12].
For simplicity, results are presented from a reduced model for
risk of failure including CD4 count, and duration of infection at
cART initiation as well as the other variables significant at the
10% level in the univariate analysis. To explore if CD4 count
was an independent predictor of risk of failure after accounting
for virological status, we refitted the final model adjusting for
HIV-RNA (log 10 scale) at cART initiation. To better understand
patterns of discontinuation, Kaplan-Meier methods were used
to estimate the risk of treatment interruption, defined as at least
30 days with no antiretroviral therapy, according to CD4 count
and HIV duration at cART initiation.
For the subset of patients for whom we were able to match
HIV nucleotide sequences in the UK Drug Resistance
Database [13], we estimated the predictors of detection of one
or more drug resistance mutations using the same methods as
for virological failure. Drug resistance mutations were defined
using the Stanford HIV drug resistance algorithm which assigns
a drug resistance susceptibility score to each drug. The
nucleotide sequences are scanned for the presence of
mutations and the drug specific scores are summed across all
mutations in the sequence. Based on the total score, drug
susceptibility is classified as “sensitive” (score 1), “potential
low-level resistance” (score 2), “low-level resistance” (score 3),
“intermediate resistance” (score 4) and “high-level resistance”
(score 5). In our analysis, detection of drug resistance was
defined as a score 4 or 5 to at least one drug [14]. As not all
patients in the UK Register were systematically tested for drug
resistance before cART initiation, resistance tests done pre-
ART were ignored.
Finally, we estimated the long-term probability of drug
resistance in patients who initiated cART within 12 months of
HIV seroconversion using Kaplan-Meier methods to estimate
the cumulative probability of i) detection of one or more drug
HIV Infection Duration and Treatment Failure
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resistance mutations from the available nucleotide sequences
and ii) virological failure.
We performed the following sensitivity analyses to check the
robustness of results. The data were re-analysed using
fractional polynomials for duration of HIV infection and/or using
categories for calendar year of cART initiation <2001 vs. ≥2001
[13]. We further included Stanford low-level resistance (score
3) in the definition of drug resistance. Finally, to account for the
change in inclusion criteria from 3 to 1 year HIV test interval,
we reran the analyses using categories for calendar year of
cART initiation <2004 vs. ≥2004 and restricting to patients who
initiated cART ≥2004.
Ethics statement
The UK Register has research ethics approval 04/
Q2707/155. Written informed consent was obtained from all
patients enrolled after 2005. The Ethics committee did not
require to go back and get written consent from everyone
already enrolled at that stage. No incentives were given to
patients to participate the study.
Results
Baseline characteristics
Of the 2826 patients enrolled in the UK Register of HIV
Seroconverters, 1751 were excluded as follows: 1066 did not
received cART, 468 were not ART-naive at cART initiation, 134
had no CD4 recorded in the 6 months before cART initiation
and 83 had no HIV-RNA after 6 months of cART initiation. The
1075 patients included were mostly homosexual men who
started with an NNRTI-based cART regimen (Table 1). Median
CD4 count [IQR] at cART initiation was 272 [190,370] cells/
mm3. Discontinuation of treatment rates were high with 264
(25%) discontinuing cART at least once. Among those who
discontinued, 81 restarted treatment after a median [IQR] of 7
[3,15] months. The Kaplan-Meier cumulative probability of
discontinuing treatment was 13% (95% CI 11%,15%) and 32%
(28%,35%) at 1 and 8 years after cART initiation, respectively.
Patients with higher CD4 count and shorter HIV duration at
cART initiation were more likely to interrupt treatment (both p
log-rank tests <0.001) (Figure 1).
Two hundred and thirty patients started cART within 12
months of HIV seroconversion with median CD4 count of 390
[233,538] cells/mm3 at initiation. Treatment discontinuation in
this subgroup was more common (42%) compared to the
overall included patients after median cART duration of 7 [3,13]
months, reflecting a common practice during the study period
of prescribing short-course therapy in primary HIV infection.
Effect of HIV infection duration on risk of virological
failure
One hundred sixty three (15%) experienced at least one
episode of virological failure during a follow-up of 4524 person
years (PY). The crude rates of failure were 3.6 (95% CI 3.1,4.2)
events per 100 PY overall and 3.7 (2.0,6.3), 3.4 (2.0,5.3) and
3.6 (3.0,4.3) for individuals with HIV infection duration at cART
Table 1. Baseline characteristics of 1075 seroconverters
initiating cART and included in analysis and of 230 early
cART initiators, i.e. within 12 months of the estimated date
of HIV seroconversion.
 Overall Early cART initiation
 N 1075 N 230
Male, N(%) 1009 94% 213 93%
Risk group, N %     
Sex between men 948 88% 199 87%
Sex between women and men 90 8% 25 11%
Injecting drug use 29 3% 2 1%
Unknown/Other 8 10% 4 2%
Calendar year of cART initiation,
median IQR 2003 [2000,2007] 2003 [2000,2006]
Age at cART initiation (years),
median IQR 36 [30,42] 33 [27,39]
HIV test interval (days)*, median IQR 250 [100,470] 113 [8,244]
HIV test interval <12 months, N % 713 66% 208 90%
Laboratory evidence of acute
infection, N % 88 8% 47 20%
Duration of HIV infection cART
initiation (years since date of HIV
seroconversion), median IQR
3.1 [1.2,6.0] 0.4 [0.2,0.6]
CD4 cell count at cART initiation
(cells/mm3), median IQR 272 [190,370] 390 [233,538]
CD4 cell count at cART initiation
≥500 cells/mm3, N % 112 10% 64 28%
CD4 cell count at cART initiation
≥350 cells/mm3, N % 317 3% 128 56%
HIV-RNA at cART initiation (log10
copies/mL), median IQR 5 [4.5,5.5] 5.2 [4.7,5.7]
Class of initial cART     
NNRTI 710 66% 125 54%
unboosted PI 134 12% 30 13%
boosted PI 174 16% 66 29%
3 NRTI 41 4% 6 3%
3 Class 16 1% 3 1%
Length of follow-up (years between
cART initiation and last HIV-RNA),
median [IQR]
5 [2,8] 5 [2,8]
Discontinued treatment during follow-
up^, N % 264 25% 97 42%
Time from cART initiation to first
episode of discontinuation (months)^,
median [IQR]
12 [3,31] 7 [3,13]
Duration of first episode of
discontinuation (months)^, median
[IQR]
14 [5,32] 29 [13,45]
Restarted cART after the first
episode of discontinuation, N % 251 95% 94 96%
Duration of second episode of
discontinuation (months)^, median
[IQR]
8 [3,19] 8 [3,54]
At least one episode of virological
failure, N % 163 (15%) 33 (14%)
HIV Infection Duration and Treatment Failure
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initiation ≤3 months, 4-12 months and >12 months,
respectively.
A summary of the univariate and multivariable Cox models of
the association of covariates, i.e. characteristics at cART
initiation, on the risk of failure is presented in Table 2. While
higher CD4 count, age ≥36 years at cART initiation and
calendar period ≥2000 were independently associated with
lower risk of failure, we found no evidence of an effect of
duration of HIV infection. Patients who started cART in or after
2000 had significantly lower hazard of experiencing virological
failure compared to those who started before this year (hazard
ratio (HR) 0.29, 95% CI 0.21,0.39, p≤0.001). We did not find
any other significant effect of the explored covariates on the
risk of virological failure. While there was evidence that
unboosted PI-based initial cART and presentation during acute
infection were associated with a higher risk of failure in the
univariate analysis, these associations disappeared after
adjustment for CD4 count and calendar year of cART initiation.
When we refitted the multivariable model to include HIV-RNA
at cART initiation, neither HIV-RNA nor CD4 count at cART
initiation were significantly associated with risk of failure (HR
1.08 (95% CI 0.86,1.37), p=0.498 and 0.85 (0.69,1.06),
p=0.148, respectively). We found similar results when using
calendar year of cART initiation <2001 vs. ≥2001 and <2004
vs. ≥2004 and restricting to patients who initiated cART ≥2004.
Effect of HIV infection duration on risk of resistance
There were 270 episodes of virological failure and, of these,
36 (13%) were followed by a genotyping test within 12 months.
Two hundred and thirty-three patients (21%) had a least one
HIV nucleotide sequence during follow-up, of whom 82 (36%)
had evidence of drug resistance, 72 while on cART. Median
[IQR] HIV-RNA in the 3 months before the genotypic resistance
test was 5.0 [4.5,5.5] log10 copies/mL. The crude drug
resistance rate was 1.4 (95% CI 1.1,1.7) events per 100
person-years (PY) of follow-up overall (including periods off
ART), and 1.3 (95% CI 1.1,1.7) events/100 PY on cART. The
most common resistance mutations were non-nucleoside
Table 1 (continued).
 Overall Early cART initiation
 N 1075 N 230
At least one nucleotide sequence
available, N % 233 (22%) 76 (33%
Drug resistance to at least 1 drug
detected, N % 82 8% 13 6%
Crude rate of resistance overall,
events/100 person years, 95 % CI 1.4 (1.1,1.7) 1.1 (0.6,1.8)
Crude rate of resistance while on
cART, events/100 person years, 95%
CI
1.3 (1.1,1.7) 1.1 (0.5,2.1)
*. Time elapsing between the last negative and first positive HIV antibody test
^. Treatment discontinuation was defined as at least 30 days without any
antiretroviral drugs
doi: 10.1371/journal.pone.0075608.t001
reverse transcriptase inhibitors (NNRTI) (49 patients) and
nucleoside reverse-transcriptase inhibitor (NRTI) drugs (64
patients), while resistance to PIs and nucleotide transcriptase
inhibitors (NtRTI) were less common (14 and 19 patients,
respectively). Similarly to the virological failure analysis, we
found no evidence of an association between duration of HIV
infection at cART initiation and development of drug resistance
when this was treated as the outcome in the unadjusted and
adjusted analyses. Moreover, we found similar significant
effects for the other covariates with the adjusted hazard ratio
for cART initiation ≥2001 vs <2001 being 0.53 (0.30,0.96).
Long term probability of drug resistance in patients
who initiated cART early
Of the 230 patients who initiated cART early, 106 (45%) had
a resistance test while ART-naïve, of whom 6 (6%) had
evidence of transmitted drug resistance. Thirteen developed at
least one drug resistance-associated mutation based on the 76
available HIV-RNA nucleotide sequences, 10 while known to
be on cART. The estimated crude drug resistance rate was 1.1
(95% CI 0.6,1.8)/100 PY overall (including periods off ART)
and 1.1 (95% CI 0.5,2.1)/100 PY while on cART. Thirty-three
(14%) of 230 early initiators experienced at least one episode
of virological failure during 936 PY follow-up. Figure 2 depicts
the cumulative probabilities of detection of drug resistance
mutations and of virological failure by time since cART
initiation. By 8 years following cART initiation 7% (95%
confidence intervals 4%,11%) are estimated to have evidence
of drug resistance, and 19% (13%,25%) of previous or current
virological failure. Results did not materially change when
Stanford score 3 was considered as indicative of drug
resistance.
Discussion
To our knowledge, this is the first study to examine the role
of HIV infection duration at cART initiation on the risk of
virological failure and development of drug resistance, and to
provide estimates of the risk of these two events for patients
initiating cART within 12 months of HIV seroconversion.
Although, as expected, we found that higher CD4 count at
cART initiation was associated with lower risks of failure and
resistance, we found no evidence to suggest that this was the
case for infection duration at the time cART is initiated. Of note,
however, we also found that, for patients initiating cART within
12 months of infection, the proportion developing resistance by
8 years lay between 7% and 19% comparable to estimates
reported for individuals initiating cART during chronic infection
[9]. Furthermore, the rate of detection of drug resistance in the
early initiators was 1.1 (95% CI 0.6,1.8) /100 PY, similar to the
rate reported by the Swiss HIV cohort study based on
seroprevalent patients starting cART, i.e. individuals with
unknown date of HIV infection [15].
The rate of cART discontinuation among those initiating
within 12 months of HIV infection and/or with CD4 count >350
cells/mm3 was high in our cohort (Figure 1). This is because
short-course cART in primary HIV infection was a common
treatment strategy in the United Kingdom until recently (median
HIV Infection Duration and Treatment Failure
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Figure 1.  Hazard ratio (HR) k of treatment interruption by duration of HIV infection (as time between HIV seroconversion
and cART initiation) and CD4 count at cART initiation.  
doi: 10.1371/journal.pone.0075608.g001
HIV Infection Duration and Treatment Failure
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[IQR] cART duration being 7 [3,13] months). Treatment
interruption, at least in chronic infection, is no longer
recommended [16] and the recent results from SPARTAC have
shown only a modest delay in disease progression after a 48-
week cART course in primary HIV infection [17]. Nevertheless,
this high rate provides a good illustration of what might be
expected from frequent treatment discontinuation if
asymptomatic HIV-positive individuals start cART early in the
course of HIV disease.
Our study does not therefore provide any evidence of early
cART initiation being associated with increased risk of
virological failure and development of drug resistance after
cART initiation. These findings should be interpreted with
caution, however, as they do not address the question of when
to start cART, because of the dangers of inferring treatment
effects from observational data [18,19]. In this non-randomised
setting, the effect of HIV infection duration, or CD4 count at
cART initiation, on the risk of failure could be partially explained
by confounding if the reasons for starting treatment early,
rather than delaying until chronic infection, were also
associated with the risk of developing resistance and failure. In
addition, we studied risk of resistance using cART initiation as
baseline. From the point of view of a person in whom the
decision whether to initiate cART is being made, any delay in
initiation represents a delay in the time before they put
themselves at risk of treatment-acquired resistance. The
question, therefore, still remains as to whether it is beneficial to
initiate cART early and can only be addressed within
randomised clinical trials. These should be designed to also
estimate the prevalence and incidence of clinically-relevant
drug resistance mutations over relatively long follow-up time.
The ongoing START trial has such an aim and is currently
recruiting [20].
Other studies have examined predictors of resistance
[8-10,21-23] and failure [24,25] in seroprevalent cohorts. Our
finding that higher CD4 count at cART initiation was an
independent predictor of risk of failure and drug resistance was
supported by two of these studies [9,10,24]. In contrast with
published findings from observational studies and clinical trials,
we found no evidence that the use of boosted PI-based cART
was associated with a lower risk of failure and resistance
compared to NNRTI [9,21-27].
Our study has a number of limitations. First, treatment
discontinuation was based on prescribed medication rather
than actual drugs taken and we may, therefore, have
underestimated the frequency of interruption. Second, a non-
negligible proportion of patients in our study started
combinations that are less potent than those in current use in
the UK. HIV genotyping, as is currently recommended and
used in routine practice in the UK, is likely to further reduce the
risk of virological failure and resistance. Third, we were able to
match a low proportion of treated individuals experiencing
Table 2. Predictors of risk of virological failure following cART initiation for 1075 patients.
 Univariable Cox models  Multivariable Cox model
 Hazard Ratio 95% CI P-value*  Hazard Ratio 95% CI P-value*
Duration at cART initiation (months since date of HIV seroconversion)          
≤3 1   0.933  1   0.592
 4-12 0.89 (0.43, 1.82)   0.76 (0.36, 1.58)  
≥12 0.86 (0.53, 1.73)   0.72 (0.38, 1.36)  
CD4 count at cART initiation (ln cells/mm3 increase) 0.84 (0.68, 1.02) 0.087  0.82 (0.69, 0.98) 0.033
Age at cART initiation (years)          
<36 1     1   0.08
≥36 0.64 (0.47, 0.87) 0.005  0.75 (0.55, 1.03)  
Calendar year of cART initiation          
<2000 1     1   <0.001
≥2000 0.29 (0.21, 0.39) <0.001  0.32 (0.22, 0.47)  
Identification during acute infection 0.71 (0.52, 0.97) 0.030  0.82 (0.59, 1.14) 0.236
Female 0.49 (0.22, 1.20) 0.120      
Risk group          
Sex between men 1   0.183      
Injecting Drug users 0.59 (0.19, 1.86)       
Sex between a woman
and a man 0.58 (0.29, 1.19)       
Class of initial cART          
NNRTI 1   <0.001  1   0.639
Unboosted PI 2.68 (1.87, 3.84)   1.18 (0.77, 1.79)  
Boosted PI 1.02 (0.62, 1.68)   1.43 (0.76, 2.69)  
Other 1.48 (0.79, 2.78)   1.16 (0.70, 1.94)  
*. P-values for Wald test for continuous and binary variables and Wald test for heterogeneity for categorical variables
doi: 10.1371/journal.pone.0075608.t002
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failure with HIV nucleotide sequences. Estimates of failure due
to the development of drug resistance are, therefore, likely to
lie between our estimates of resistance (from nucleotide
sequences) and virological failure (from HIV-RNA results).
Moreover, given that not all patients were genotyped shortly
following infection, some resistance-associated mutations may,
in fact, have been transmitted. It is, therefore, possible that our
estimates of risk of resistance are somewhat pessimistic.
Fourth, although it is recommended that HIV testing be offered
at least annually to at risk individuals in the UK [28], is
confidential and free of charge, rates of previous HIV testing
are low among newly-diagnosed individuals [29]. Individuals
identified as seroconverters, and enrolled into the UK Register,
are likely, therefore, to not be representative of all those
infected. Rates of virological failure reported here may not,
therefore, be generalizable, although it is worth noting that
CASCADE has reported no evidence of a difference in HIV
disease progression and outcome between seroconverters and
those with prevalent HIV infection (individuals without
estimated dates of HIV seroconversion [30]. In any case, it is
not possible, by definition, to assess the role of HIV infection
duration without using data from seroconverters. Finally,
individuals included in our study are from a resource-rich
country and results may not apply to other settings.
In conclusion, we found no evidence to suggest that initiation
of cART in early HIV infection is predictive of increased risk of
virological failure while on treatment and drug resistance.
Moreover, the long-term risk of failure in patients who initiated
early, was relatively low. Our findings should provide comfort to
patients and their clinicians that early initiation of cART is
unlikely to have a detrimental impact on the long-term risk of
drug resistance. Nevertheless, data from randomised clinical
trials are needed to shed light on the long term clinical benefits
and side effects, including development of drug resistance, of
early versus delayed cART initiation.
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